MedTrace Logo

Exenatide Once Weekly for Smoking Cessation

NCT02975297 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2021-01-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to identify a potential new treatment for smoking cessation.

Conditions

  • Smoking Cessation

Interventions

DRUG

Exenatide

Exenatide Injectable Product will be administered at a dose of 2 mg subcutaneously once a week for 6 weeks.

DRUG

NRT

Nicotine Patch (21mg) / 24 hours.

BEHAVIORAL

Counseling

Brief individual behavioral smoking cessation counseling.

DRUG

Placebo

Normal saline.

Sponsors & Collaborators

  • The University of Texas Health Science Center, Houston

    lead OTHER

Principal Investigators

  • Luba Yammine, PhD · The University of Texas Health Science Center, Houston

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2020-01-03
Completion
2020-01-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02975297 on ClinicalTrials.gov